Atrial Septostomy — Cost, Top Hospitals & Success Rates | MyMedicPlus

Atrial septostomy is a cardiac procedure that creates or enlarges an opening in the wall (septum) between the right and left atria of the heart. Unlike atrial septal defect closure — which seals an existing hole — septostomy intentionally creates a controlled inter-atrial communication to achieve specific haemodynamic goals. The most common indication is severe, treatment-refractory pulmonary arterial hypertension (PAH), where septostomy creates a right-to-left shunt that decompresses the failing right ventricle by allowing blood to bypass the high-resistance pulmonary circulation, improving systemic cardiac output and relieving right heart failure symptoms at the cost of mild arterial desaturation.

The procedure is performed percutaneously in the cardiac catheterisation laboratory under general anaesthesia with echocardiographic guidance. The most commonly used technique is balloon atrial septostomy, in which a catheter is passed from the femoral vein through the inferior vena cava to the right atrium, the atrial septum is crossed, and a balloon is inflated and forcibly withdrawn through the septum to tear it to the desired size. Graded balloon dilation using progressively larger balloons titrates the size of the defect to achieve target haemodynamics. Blade septostomy — using a small retractable blade catheter to incise the septum before balloon dilation — is used for thicker septa, as in adults with chronic PAH.

Atrial septostomy is a palliative procedure for severe PAH — bridging patients to lung transplantation or providing relief when transplant is unavailable — and is not curative of the underlying pulmonary vascular disease.

Severe pulmonary arterial hypertension (WHO Group 1) is the primary indication for atrial septostomy when right heart failure is refractory to maximal medical therapy (prostacyclin analogues, ERA, phosphodiesterase-5 inhibitors), patients have recurrent syncopal episodes from low cardiac output, or as a bridge to lung transplantation. Creating a right-to-left shunt at the atrial level maintains systemic perfusion by supplementing left heart filling from the right atrium during periods of acute right ventricular decompensation.

In neonates and infants with certain complex congenital heart defects, atrial septostomy is a life-saving emergency procedure. Transposition of the great arteries (TGA) requires an adequate inter-atrial communication to allow mixing of oxygenated and deoxygenated blood while awaiting definitive surgical repair — the Rashkind balloon septostomy performed in the neonatal period is a classic intervention for TGA. Total anomalous pulmonary venous drainage (TAPVD) with obstructed pulmonary venous return and hypoplastic left heart syndrome may also require septostomy as a stabilising measure.

Adults with severe PAH are candidates for septostomy when they have recurrent episodes of syncope or pre-syncope despite maximised drug therapy, are in WHO functional class III–IV with deteriorating quality of life, and are either awaiting lung transplantation or are not candidates for transplant. Pre-procedural assessment includes right heart catheterisation confirming very high pulmonary vascular resistance and right heart pressures, and echocardiographic assessment of right and left ventricular function. Adequate left ventricular end-diastolic volume is required to tolerate the increased preload from the right-to-left shunt.

Absolute contraindications include severe left ventricular dysfunction (unable to accommodate the increased filling from shunt), severe hypoxaemia at rest (oxygen saturation below 90% on room air — further desaturation from the right-to-left shunt would be intolerable), mean right atrial pressure above 20 mmHg (predicting high procedural mortality), and complete absence of a viable left ventricle. Neonatal septostomy for TGA is performed emergently in any haemodynamically compromised neonate with inadequate inter-atrial mixing.

Balloon atrial septostomy (BAS) uses a balloon-tipped catheter passed through the foramen ovale or a patent ductus or across the septum via transseptal puncture. The balloon is inflated in the left atrium and rapidly withdrawn into the right atrium, tearing the thin septum to create an inter-atrial defect. In neonates with TGA, a single or double BAS is usually sufficient. In adults with PAH and thicker septa, graded balloon dilation using progressively larger balloons (up to 16–20 mm) is performed under haemodynamic guidance.

Blade atrial septostomy uses a Park blade catheter (with a retractable small blade at the tip) to make multiple cuts in the septum before balloon dilation, particularly useful for fibrotic or thick adult atrial septa. Radiofrequency perforation of the septum with RF-assisted guidewire crossing may facilitate transseptal access when conventional needle techniques fail. Stent-based inter-atrial shunt devices (e.g., atrial flow regulator, Corvia IASD) are being investigated as controlled-size, adjustable shunt options for heart failure with preserved ejection fraction.

Selecting the most appropriate Atrial Septostomy approach requires a structured assessment of patient-specific factors. The treating specialist evaluates disease severity, prior treatment history, comorbidities, and patient preferences before recommending a specific protocol. Combination approaches are often more effective than monotherapy — integrating pharmacological, procedural, or rehabilitative elements to address multiple disease mechanisms simultaneously. Dose or intensity is titrated incrementally based on clinical response, tolerability, and objective outcome measures. In patients with refractory disease or inadequate response to first-line protocols, escalation to higher-intensity or specialist-delivered treatment options is indicated. Multidisciplinary team (MDT) review ensures that surgical, medical, and allied health perspectives are integrated into the final management plan, particularly for complex or high-risk cases where multiple treatment pathways are viable and the risk-benefit balance requires careful deliberation.

In adults with severe PAH, successful atrial septostomy achieves acute haemodynamic improvement with increased cardiac index, reduced right atrial pressure, and subjective improvement in dyspnoea and syncope frequency. Observational series report 1-year survival of 60–75% following septostomy in selected severe PAH patients, compared to expected survival of 30–50% in historical controls on medical therapy alone before the biologic era. Quality of life improvement — particularly resolution of recurrent syncope — is a consistent and meaningful benefit.

In neonates with TGA, Rashkind balloon septostomy is immediately life-saving, increasing arterial oxygen saturation from critically low levels to acceptable values (SaO2 70–80%) within minutes of the procedure, allowing the neonate to stabilise before definitive arterial switch operation. Outcome data for neonatal BAS for TGA show excellent survival to definitive surgical repair (greater than 95%) when performed promptly.

Atrial septostomy in adults with severe PAH carries a procedural mortality of 5–15% in reported series, reflecting the extreme haemodynamic fragility of these patients. Acute catastrophic right-to-left shunting leading to severe systemic hypoxaemia and cardiovascular collapse is the most feared complication, particularly if the created defect is too large for the patient's baseline haemodynamics. Pericardial tamponade from inadvertent perforation of the atrial wall is a rare but serious risk. Paradoxical embolism (systemic embolism via the new right-to-left shunt) may occur in patients with concurrent pulmonary embolism or right heart thrombus.

In neonates, balloon septostomy is generally very well tolerated with low procedural risk, though cardiac perforation and pericardial effusion are reported in less than 1% of cases. Inadequate tearing of the septum may require repeat dilation. Acute haemodynamic deterioration during neonatal BAS is managed with immediate prostaglandin E1 infusion to maintain ductal patency.

Following adult atrial septostomy for PAH, patients are observed in a specialist cardiac intensive care unit for 3–7 days with continuous haemodynamic monitoring, assessment of arterial oxygen saturation, and optimisation of right heart supportive therapies. Echocardiography confirms defect size and shunt direction post-procedure. Ongoing PAH-targeted medical therapy continues alongside the palliative haemodynamic benefit of the septostomy.

For neonates following Rashkind septostomy for TGA, stabilisation in the neonatal cardiac intensive care unit typically achieves clinical stability within hours. Definitive arterial switch operation is usually performed within the first 2 weeks of life. Long-term follow-up of children and adults who have undergone atrial septostomy involves specialist cardiac centre review with echocardiography, right heart catheterisation at 3–6 monthly intervals, and pulmonary hypertension multidisciplinary team assessment.

Atrial septostomy in the United States, performed in a specialist centre for severe PAH or congenital heart disease, typically costs USD 30,000–70,000 inclusive of catheterisation laboratory, physician, and hospital stay costs. Neonatal emergency BAS may be factored into the overall management cost of TGA, which ranges from USD 80,000–150,000 for the complete surgical package.

Leading congenital and pulmonary hypertension cardiac centres in India perform atrial septostomy at approximately USD 5,000–10,000, and in Thailand at USD 8,000–15,000 — savings of 60–80% for international patients. Centres such as Apollo Hospitals and Fortis Heart Institute in India, and Bumrungrad Heart Centre in Thailand, have experienced interventional cardiologists with high volumes of complex cardiac catheterisation including septostomy.

Several key factors determine the final cost of Atrial Septostomy: clinical complexity of the individual case, the specific technique or protocol selected, specialist time required, imaging and laboratory testing, implant or device costs where applicable, and the duration of post-treatment monitoring. Geographic location exerts a strong influence — urban tertiary-care centres in high-income countries charge premium rates, while equivalent accredited care in India, Thailand, Turkey, and Mexico provides comparable clinical outcomes at 50–75% lower cost. Patients seeking international treatment should factor in travel, accommodation, and the cost of follow-up care on return home. Private health insurance coverage varies considerably; patients should obtain pre-authorisation in writing and confirm what components of the treatment pathway are included. Many patients access government healthcare subsidies or medical financing plans to spread the cost of elective and semi-elective procedures.

For severe PAH, lung transplantation (bilateral sequential lung transplant or heart-lung transplant) remains the only curative option, with 5-year survival of 50–60% at experienced centres. Septostomy serves as a bridge to transplantation. Escalating medical combination therapy — triple combination of prostacyclin analogue (selexipag, epoprostenol), endothelin receptor antagonist (bosentan, macitentan), and phosphodiesterase-5 inhibitor (sildenafil, tadalafil) — has substantially improved PAH outcomes and should be optimised before considering invasive procedures.

For neonatal TGA, the definitive alternative to emergency palliation is prompt arterial switch operation (ASO) — ideally within the first 2 weeks of life. Atrial septostomy is a bridge to ASO, not a competing definitive treatment. Prostaglandin E1 infusion to maintain ductal patency provides additional mixing and is used alongside septostomy in critically ill neonates.